Terms: = Leukemia AND HIST1H4I, MGC24116, 8294, P62805
4 results:
1. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.
Platzbecker U; Middeke JM; Sockel K; Herbst R; Wolf D; Baldus CD; Oelschlägel U; Mütherig A; Fransecky L; Noppeney R; Bug G; Götze KS; Krämer A; Bochtler T; Stelljes M; Groth C; Schubert A; Mende M; Stölzel F; Borkmann C; Kubasch AS; von Bonin M; Serve H; Hänel M; Dührsen U; Schetelig J; Röllig C; Kramer M; Ehninger G; Bornhäuser M; Thiede C
Lancet Oncol; 2018 Dec; 19(12):1668-1679. PubMed ID: 30442503
[TBL] [Abstract] [Full Text] [Related]
2. Rituximab-based chemoimmunotherapy prolongs survival of patients with chronic lymphocytic leukemia independently of the time of administration.
Delgado J; Ghita G; Baumann T; Santacruz R; Dlouhy I; Aymerich M; Rozman M; Creus N; Pereira A; Montserrat E
Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):73-9. PubMed ID: 24126217
[TBL] [Abstract] [Full Text] [Related]
3. Near-tetraploidy in childhood B-cell precursor acute lymphoblastic leukemia is a highly specific feature of ETV6/RUNX1-positive leukemic cases.
Attarbaschi A; Mann G; König M; Steiner M; Dworzak MN; Gadner H; Haas OA;
Genes Chromosomes Cancer; 2006 Jun; 45(6):608-11. PubMed ID: 16552772
[TBL] [Abstract] [Full Text] [Related]
4. Childhood acute lymphoblastic leukemia immunophenotypes and their prognostic significance: experience of the IGCI-study in 389 children. International Society for Chemo-immunotherapy (IGCI-Vienna) Cooperative Group.
Holowiecki J; Koehler M; Zintl Z; Kardos G; Lutz D; Krzemien S; Rewesz T; Brugiatelli M; Callea V; Kachel L
Leuk Lymphoma; 1992 Jun; 7(3):225-34. PubMed ID: 1477650
[TBL] [Abstract] [Full Text] [Related]
